# The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial

> **NCT06946901** · PHASE2 · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Hyperthermic Intraperitoneal Chemotherapy
- Peritoneal Metastatic Pancreatic Cancer

## Interventions

- **COMBINATION_PRODUCT:** Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin + Systemic AG Chemotherapy

## Key facts

- **NCT ID:** NCT06946901
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2026-04-03
- **Final completion:** 2027-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06946901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06946901, "The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06946901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*